Neoadjuvant Therapy in Pancreatic Cancer: An Emerging Strategy
Pancreatic adenocarcinoma (PDAC) is the fourth leading cause of cancer deaths among men and women, being responsible for 6% of all cancer-related deaths. Surgical resection offers the only chance of cure, but only 15 to 20 percent of cases are potentially resectable at presentation. In recent years,...
Saved in:
| Main Authors: | Alessandro Bittoni, Matteo Santoni, Andrea Lanese, Chiara Pellei, Kalliopi Andrikou, Cascinu Stefano |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2014/183852 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Should every patient with pancreatic cancer receive perioperative/neoadjuvant therapy?
by: Ulrich Nitsche, et al.
Published: (2016-01-01) -
The effect of neoadjuvant chemoradiation therapy in resectable pancreatic cancer was independent of intratumoral vascularization
by: Tomomi Yasue, et al.
Published: (2025-07-01) -
Pathogenic and Diagnostic Potential of BLCA-1 and BLCA-4 Nuclear Proteins in Urothelial Cell Carcinoma of Human Bladder
by: Matteo Santoni, et al.
Published: (2012-01-01) -
Complement activation in tumor microenvironment after neoadjuvant therapy and its impact on pancreatic cancer outcomes
by: Xiaofei Zhang, et al.
Published: (2025-03-01) -
Pancreatic Cancer Resectability After Neoadjuvant Treatment: An Imaging Challenge
by: Ioannis Christofilis, et al.
Published: (2025-07-01)